Synexus Recruits 20% of All Patients in Crestor Jupiter Study

MANCHESTER, England--(BUSINESS WIRE)--Using just eight of its 14 hub sites Synexus® recruited and randomised more than 2740 of the 15,000 patients involved in AstraZeneca’s Crestor Jupiter study into cardiovascular disease.